Navigation Links
COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
Date:6/14/2011

TUESDAY, June 14 (HealthDay News) -- A mist inhaler with the drug Spiriva is associated with a 52 percent increased risk of death among people with chronic obstructive pulmonary disease (COPD), a new review shows.

The mist inhaler with the soluble form of Spiriva (tiotropium) is approved in 55 countries, but is not yet approved in the United States. However, the powdered form of Spiriva is commonly used to treat COPD patients in the United States.

"Tiotropium is an inhaled drug used commonly in the treatment of COPD. Its major purpose is to reduce obstruction to airflow," explained Dr. Mark Rosen, director of pulmonary rehabilitation at North Shore University Hospital in Manhasset, N.Y., and Long Island Jewish Medical Center in New Hyde Park, N.Y.

"In the U.S., it is available only in the 'Handihaler' device that delivers the drug in a powder form," said Rosen, who was not involved in the new study. "Another form of tiotropium is available in Europe, but not the U.S., in a mist using a 'Respimat' device."

In the new study, researchers led by Dr. Sonal Singh, an assistant professor of general internal medicine at the Johns Hopkins University School of Medicine in Baltimore, analyzed the findings of five published studies that included a total of more than 6,500 patients. They compared the mist inhaler with Spiriva against a mist inhaler with a placebo.

Those who used the inhaler with Spiriva were 52 percent more likely to die than those who used the inhaler with the placebo. There was one excess death due to the mist inhaler with Spiriva for every 124 patients who were treated for a year. Cardiovascular disease is the main reason for the increased risk of death, Singh said.

"What we think is going on is that the mist inhaler is delivering a higher concentration of tiotropium than it should and that may be increasing the risk of death," Singh said in a Hopkins news release.

Rosen said that American patients need not be alarmed, but the findings should give regulators something to consider.

"It is not known why the results of the Handihaler and Respimat are so different, but [it] will give the FDA pause before approving the Respirat in this country," he said.

Another expert said Spiriva can have other serious side effects.

"While it's difficult to compare the different delivery systems' effect on mortality, it is known that certain patients with glaucoma or a history of urinary retention should not use this drug," said Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City. "It can also cause paradoxical bronchospasm, and severe allergic reactions. Tiotropium causes dry mouth, and can elevate heart rate. Since it is used in COPD, which is associated with cardiac conditions, other cardiac complications are possible."

Patients need to discuss the risks and benefits of COPD treatments with their doctors, Singh advised.

The study appears online June 14 in the BMJ.

COPD, the fourth leading cause of death worldwide, includes emphysema and bronchitis and is typically caused by decades of smoking.

More information

The American Academy of Family Physicians has more about COPD.

-- Robert Preidt

SOURCES: Mark Rosen, M.D., director, pulmonary rehabilitation, North Shore University Hospital, Manhasset, N.Y. and Long Island Jewish Medical Center, New Hyde Park, N.Y.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; Johns Hopkins Medical Institutions, news release, June 14, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients
2. Good Sleep Could Boost Undergrads Learning Capacity
3. Nanotubes could pose health risk to production line staff, study suggests
4. A scientific breakthrough at the IRCM could help understand certain cancers
5. Screening high-risk employees for sleep apnea could save a corporation millions of dollars
6. 1 in 5 heart-attack deaths could be prevented with new drug
7. Simple test could hold key to early diagnosis of cancers
8. MyCare -- the card that could save your life
9. Tai chi could be key to overcoming cognitive effects of chemotherapy
10. Tens of thousands of lives could potentially be saved by key heart failure therapies
11. Groundbreaking male infertility test could bring hope to millions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
(Date:2/27/2017)... ... February 27, 2017 , ... ... is proud to announce a new informational post on robotic hair transplantation. San ... Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five states ... And the need for advanced services is growing. , Project WE vs C ... in collaboration with their non-profit partners in their fight against cancer and in support ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards & ... International Social Design Awards. , The 7th A' Social Design Award is ... Institutions worldwide with realized projects and conceptual works. , The first phase of ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... PA (PRWEB) , ... February 26, 2017 , ... ... and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. ... Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)... AUSTIN, Texas , Feb. 27, 2017  International Biophysics ... Austin, Texas , today announced a 34% revenue growth ... a 53% increase in unit sales.  This growth was fueled ... in addition to the expansion of its global ... Shockley, Jr., International Biophysics, CEO, "As we enter our 25 ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology: